Novel heterocyclic dertvatives of 2-quinolinone associated with antibacterial and antitumor potencies

Article abstract of DOI:10.3987/COM-12-12523

3-(2,2-Dichloroacetyl)-4-hydroxy-1-methylquinolin-2(1H)-one (2) was utilized to obtain several new quinolinones bearing imidazole, quinoxaline, 1,2,4-triazine, pyridotriazine and triazolotriazine heterocycles as substituents at position 3. Condensation of

Full text of DOI:10.3987/COM-12-12523

HETEROCYCLES, Vol. 85, No. 6, 2012
2421
HETEROCYCLES, Vol. 85, No. 10, 2012, pp. 2421 - 2436. © 2012 The Japan Institute of Heterocyclic Chemistry
Received, 8th June, 2012, Accepted, 25th July, 2012, Published online, 16th August, 2012
DOI: 10.3987/COM-12-12523
NOVEL HETEROCYCLIC DERTVATIVES OF 2-QUINOLINONE
ASSOCIATED
POTENCIES
WITH
ANTIBACTERIAL
AND
ANTITUMOR
Hany M. Hassanin* and Somaya M. El-edfawy
Department of Chemistry, Faculty of Education, Ain Shams University, Roxy,
Cairo, Egypt 11757
Corresponding author: E-mail: hanyhassnin@yahoo.com
Abstract – 3-(2,2-Dichloroacetyl)-4-hydroxy-1-methylquinolin-2(1H)-one (2) was
utilized to obtain several new quinolinones bearing imidazole, quinoxaline,
1,2,4-triazine, pyridotriazine and triazolotriazine heterocycles as substituents at
position 3. Condensation of compound 2 with aminotriazine 11 afforded the
iminone 12 which was subjected to annellation reactions leading to some new
quinolinones fused at face [c]; viz. pyrazole, pyrimidine and benzodiazepine.
Structure of the new compounds was confirmed by spectral and elemental analyses.
The synthesized compounds were screened in vitro for their antimicrobial and
antitumor activities.
INTRODUCTION
The chemistry of quinolinone derivatives has been of increasing interest since many of these compounds
have found useful chemotherapeutic agents. For example, quinolinones revealed potential hepatitis C
polymerase inhibitors.1,2 Also, many quinolinone derivatives were found active as microsomal
prostaglandin E2 synthase-13 and selective iNOS.4 Many quinolinone derivatives have been found active
as antibacterial,5,6 anti-hepatitis B virus (HBV) activities,7,8 anti-HIV-1 agents.9 Combination of pyrazole
nucleus with quinoline moiety, in one molecular framework, was reported in literature to possess
biological activity.10-12 Also, pyrimido[5,4-c]quinolin-5(1H)-ones showed antioxidant and toxicological
activities.13 Many pyrimidoquinolines have antiviral activity at nanomolar concentrations against
HIV-1,14 and exhibited good antibacterial and antifungal activity.15 In addition, imidazole derivatives
display efficacy in human tumor xenograft models.16 On the other hand, 1,2,4-triazine derivatives have
been shown to have significant antitumor activities with simultaneous non-toxicity to human normal cell
line and HSF cells.17 Furthermore, 1,2,4-triazine derivatives exhibited comparable antibacterial potencies

2422
HETEROCYCLES, Vol. 85, No. 6, 2012
in vitro as that of ampicillin,18 and significant broad cytotoxic activity against cancer cell in low
micromolar range.19 Based on these findings, it was of interest to introduce a new series of quinoline and
its fused systems incorporated with the above biologically active moieties, especially 1,2,4-triazine, for
the evaluation of their antimicrobial and antitumor properties.
RESULTS AND DISCUSSION
The dichloroacetyl derivative 2 was prepared by heating pyranoquinolinedione 1 with sulfuryl chloride in
dioxane (Scheme 1).20,21
O
O
O
OH
Cl
SO2Cl2
OH
Cl
dioxane
51%
O
N
O
N
Me
Me
2
1
Scheme 1
Reaction of compound 2 with some 1,3-binucleophilic reagents, namely; guanidine hydrochloride,
cyanoguanidine, and thiourea, was carried out under reflux in DMF, to afford the corresponding
1
3-imidazolylquinolinones 3a–c, respectively (Scheme 2). The H-NMR spectrum of compound 3a
revealed the presence of broad singlet at 9.74 ppm (NH). Moreover, its mass spectrum recorded the
molecular ion peak at m/z 254 which agree well with the molecular formula and supports the identity of
the structure. Also, the IR spectrum of compound 3b showed a characteristic absorption band due to the
nitrile function at 2213 cm-1. While the IR spectrum of compound 3c showed a characteristic absorption
band due to thioxo group at 1219 cm-1.
X
NH2
X
N
O
OH
N
OH
X
N
b
N
NH2
2
H
H
DMF
Cl
N
O
N
c
3
a
Me
Me
X
NH
S
NCN
76% 65% 67%
Scheme 2
Condensation of compound 2 with 1,4-N,N-binucleophiles such as o-phenylenediamine and
1,6-diaminopyridine derivative 5,22 under reflux in DMF, afforded the quinoxalinylquinolinone 4 and the

HETEROCYCLES, Vol. 85, No. 6, 2012
2423
1
pyridotriazine derivative 6, respectively (Scheme 3). The H-NMR spectrum of compound 4 showed
characteristic singlet signal at 8.30 ppm due the CHquinoxalin, in addition to the presence of aromatic
1
protons. While in the H-NMR spectrum of compound 6 the integral count of protons appeared in the
aromatic region revealed the presence of nine aromatic protons due to benzo protons of quinoline,
1,4-disubstituted benzene protons, and C3-H of pyridotriazine. IR spectrum of the compound 6 exhibits
absorption bands at 2219, 2291 cm-1 due to two nitrile groups and 1686, 1660 cm–1 due to C=Opyridone and
C=Oquinolinone, respectively.
OH
N
H2N
H2N
N
DMF
67%
N
O
Me
4
Cl
2
CN
Cl
NC
O
CN
N
N
N
NC
O
OH
N
H2N
NH2
5
DMF
N
O
67%
Me
6
Scheme 3
Reaction of compound 2 with aminoguanidine and thiosemicarbazide as 1,4-binucleophiles, under reflux
in DMF, yielded the corresponding 1,2,4-triazine derivatives 7a,b, respectively (Scheme 4). IR spectra of
compounds 7a and 7b showed characteristic absorption bands due to the NH groups at 3191 and 3126
1
cm-1, respectively. The H-NMR spectra of compounds 7a and 7b showed characteristic singlets at 8.16
ppm and 8.24 ppm, respectively, which were assigned to the proton of 1,2,4-triazine. In addition to the
deuterium exchangeable proton signal due to the N2-H, which appeared at 10.51 ppm and 12.67 ppm of
7a and 7b, respectively. Also, the mass spectrum of compound 7a revealed the molecular ion peak at m/z
269 and the base peak at m/z 242 which was in agreement with its molecular mass after loss of one
molecule of HCN. In addition, the mass spectrum of 7b revealed a molecular ion peak at m/z 286 [M+] as
the base peak, which is in good accordance with the molecular formula. Hydrazinolysis of the
1,2,4-triazine derivative 7b in DMF produced the hydrazinotriazine 8 (Scheme 4). The elemental analysis

2424
HETEROCYCLES, Vol. 85, No. 6, 2012
of the later compound showed absence of sulfur in the product revealing the replacement of the thiol
group. IR spectrum exhibited stretching vibrational bands at 3411, 3335 cm-1 due to NH2 and at 3191,
3100 cm-1 due to OH and NH groups. Also, 1H-NMR spectrum displayed three characteristic signals due
to exchangeable protons 8.43 ppm (NH2), 9.99 ppm (NH) and 13.36 ppm (OH). Moreover, the mass
spectrum revealed the molecular ion peak at m/z 284 [M+] as the base peak. Thermal cyclocondensation
of the hydrazinopyrimidine 8 with triethyl orthoformate, under fusion condition, was carried out to get the
1
triazolotriazine derivative 9 (Scheme 4). The H-NMR spectrum of the product 9 revealed the
disappearance of the NH2 signal, in addition to the appearance of singlet at 8.24 ppm assigned to the
characteristic CHtriazole. Reaction of the hydrazinotriazine 8 with [bis(methylthio)methylene]malononitrile,
in DMF under reflux, gave the compound 10. The IR spectrum of the reaction product 10 showed
characteristic absorption bands at 3323, 3183 (NH2), 2214 (C≡N), 1671(C=O). 1H-NMR spectrum of the
product 10 showed a new singlet signal at 2.88 ppm due to three protons of SCH3 group, in addition to a
broad signal at 5.22 ppm due to two protons of NH2 group.
X
X
N
O
NH
N
OH
NH2
H2N
N
H
2
a
b
7
DMF
NH
S
X
N
N
73% 77%
Me
SMe
(X = S)
DMF
NH2NH2.H2O
60%
N
H2N
N
N
NHNH2
N
N
N
MeS
MeS
N
O
N
N
N
OH
OH
N
O
N
O
N
N
OH
N
CH(OEt)3
fusion
DMF
61%
N
N
N
63%
10
8
Me
Me
Me
9
Scheme 4
Reaction of the dichloroacetyl derivative 2 with 4-aminotriazine 1123 was carried out in boiling pyridine.
Interestingly, the only product that obtained revealed absence of chlorine in its molecular formula
according to findings of elemental and mass spectral analysis. In addition, IR spectrum showed three
different strong absorption vibrations at 1709, 1667, and 1632 cm-1 indicating the presence of acetyl C=O.
1
Moreover, H-NMR spectrum revealed an azomethine C-H singlet signal at 5.93 ppm. These results
indicate that a nucleophilic replacement took place with leaving of a chlorine atom which is followed by
elimination of hydrogen chloride leading to the α-iminone 12 (Scheme 5).

HETEROCYCLES, Vol. 85, No. 6, 2012
2425
S
O
O
H
N
OH
S
H
H2N
NH
N
N
N
NH
N
N
pyridine
2
+
Cl
O
O
N
11
Me
Me
S
Me
pyridine
60%
O
OH
N
O
NH
N
N
O
12
Me
Me
NH
DMF
61%
DMF
DMF
66%
NH2NH2 .H2O
62%
H2N
NH2
H2N
NH2
NH
S
HN
N
O
N
O
S
N
O
HN
NH
N
N
HN
N
N
NH
N
S
N
N
N
13
Me
Me
O
N
N
NH
N
O
Me
Me
14
O
N
Me
15
Me
Scheme 5
α-Iminone 12, as interesting starting material, was allowed to react with some binucleophilic reagents to
prepare some new quinolinones fused at face [c] with pyrazole, pyrimidine and benzodiazepine
heterocycles. Therefore, treatment of α-iminone 12 with hydrazine hydrate, guanidine and
o-phenylenediamine, in DMF under reflux, afforded the pyrazoloquinolinone 13, pyrimidoquinolinone 14
and benzodiazepinoquinolinone 15, respectively (Scheme 5). The IR spectra of the three later products
did not reveal the absorption bands due to C4-OH and acetyl C=O vibrational frequencies that supports
1
the cyclization process. Moreover, the H-NMR spectrum of compound 13 showed signals due to two
exchangeable protons characteristic for NHpyrazole and NHtriazine at 10.53 and 13.83 ppm. Mass spectrum of
compound 13 exhibited a molecular ion peak at m/z 367, corresponding to its calculated molecular
formula. The 1H- NMR spectrum of compound 14 revealed the appearance of three exchangeable protons
due to three different N-H signals at 8.78, 11.37 and 12.23 ppm. Mass spectrum of compound 14 revealed
1
a peak at 394 assigned to molecular ion peak. While, the H-NMR spectrum of compound 15 showed
eight aromatic protons, in addition to two characteristic exchangeable singlet signals at 9.95 and 12.79
ppm due the 2 NH protons.

2426
HETEROCYCLES, Vol. 85, No. 6, 2012
Biological activity
Antimicrobial Activity
The results depicted in Table 1 showed various activities against all species of microorganisms which
suggest that the variations in the structures affect on the growth of the microorganisms. Thus, we can
conclude from these results:
1) Most of the prepared compounds showed a low to high antimicrobial activity towards Gram positive
bacteria, Gram negative bacteria and the fungal strain (Table 1).
2) Compounds 3c, 7b, 9 and 12 showed higher significant activity than the reference antibiotic
Doxymycin against Staphylococcus aureus as Gram positive bacteria.
3) Compounds 3c and 7b showed equal activity to the standard antibiotic Doxymycin against Proteus
vulgaris and Klebsiella as Gram negative bacteria, while compound 12 showed higher activity.
4) Compounds 3c, 9 and 10 showed higher activity than the standard Fluconazole as fungus strain.
5) The microbial activity of compounds 3c and 12 is due to the presence of two bioactive heterocycles as
1,2,4-triazine and quinolinone. Compounds 9 and 10 are good antimicrobial due to presence of
triazolotriazine and pyrazolyltriazine, respectively.
Table 1. The antimicrobial activity of the newly synthesized compounds
Compound
No.
Diameter of inhibition zone a (mm),
Conc. (100 µg mL-1)
S.aureus
(Gram +ve)
3
P.vulgaris
(Gram –ve)
8
Klebsiella
(Gram –ve)
5
C.albicans
(Fungal strain)
2
3a
3b
7
17
8
3
10
8
6
15
6
4
18
3
3c
4
6
3
7
10
6
4
7a
6
9
8
7b
16
8
10
2
15
11
12
4
2
8
4
9
19
14
35
12
11
10
15
-
9
19
16
4
10
8
12
20
7
16
9
13
14
5
5
11
12
15
-
9
15
3
11
-
Doxymycinb
Fluconazoleb
10
-
16
a 12 mm or less: resistant or no inhibition, 13–17 mm: moderate inhibition, 18 mm or more: strong inhibition.
b The concentration of used standard drugs was 100 µg/mL.

HETEROCYCLES, Vol. 85, No. 6, 2012
2427
The minimum inhibitory concentration (MIC)
The minimum inhibitory concentration (MIC, μg/mL) of the most active compounds 3c, 7b, 9, 10, and 12
against the selected bacterial and fungal strains were determined (Table 2). The minimum inhibitory
concentration (MIC) for these compounds show that these compounds may be considered promising for
the development of new antimicrobial agents.
Table 2. The minimum inhibitory concentration (MIC, μg/mL) of the synthesized compounds 3c, 7b, 9,
10, and 12
The selected organisms
The minimum inhibitory concentration (MIC)
3c
>50
>50
8
7b
>50
>50
25
9
25
10
>50
>50
6
12
>50
25
7
standarda
Staphylococcus aureus
Proteus vulgaris
Klebsiella
7
>50
>50
2.5
12.5
12.5
5
Candida albicans
>50
>50
7
5
a Doxymycin and Fluconazole were used as standard drugs against bacterial and fungal strains, respectively..
Antitumor activity
The antitumor activity of some of the newly synthesized compounds was investigated against Ehrlich
ascites carcinoma cells (EAC). The Antitumor efficacy of the compounds against EAC cell lines was
demonstrated compared to doxorubicin. The obtained results revealed that compounds exhibited IC50
values less than the used standard drug (doxorubicin). The triazinylquinolinones 7b, 12, 13, and 14
displayed higher activity (less IC50 values). The reason for the higher reactivity of the
triazinylquinolinones can be explained by the presence of two bioactive heterocycles, quinolinone and
1,2,4-triazinone, in one molecular frame, especially 6-methyl-5-oxo-3-thioxo-1,2,4-triazinone moiety in
compounds 12-14 which is known with its activity towards tumor cells.24 It has been reported that
quinolones are known as potent antitumor agents because they target topoisomerase II enzyme and are
considered as therapeutic promise.25 In addition, 1,2,4-triazines show promising cytotoxic effect against
different several tumor cell lines.26 Also, El-Naggar et al.,27 found that 1,2,4-triazines significantly reduce
tumor growth in EAC bearing mice. The most potent compound in this series is compound 12 due to
presence of pyrazole ring fused with quinolone. Xia et al.28 deduced that pyrazoloquinolones have the
highest cytotoxic activity against tumor cells in comparison with other qiunolone derivatives due to
highest affinity towards topoisomerase II enzyme.

2428
HETEROCYCLES, Vol. 85, No. 6, 2012
Table 3. Tumor cell growth inhibition expressed as inhibitory concentration IC50 (µM) in the presence of
the most active compounds
Compound
aIC50 (in µg/mL)
7b
29.6
27.1
33.6
29.8
39.5
12
13
14
Doxorubicin
a IC50 -the molar concentration that inhibits tumor cell growth to 50%;
EXPERIMENTAL
Melting points were determined on a digital Stuart SMP3 apparatus. Infrared spectra were measured on
1
Perkin-Elmer 293 spectrophotometer (cm-1), using KBr disks. H-NMR spectra were measured on
13
13
Gemini-300BB spectrometer 300 MHz (at 75 MHz for C), or Jeol Eca-500 MHz (at 125 MHz for C)
using DMSO-d6 or CDCl3 as a solvent and TMS (δ) as the internal standard. Mass spectra were obtained
using GC-2010 Shimadzu GC-Mass spectrometer (70 eV). Elemental microanalyses were performed on a
Perkin–Elmer CHN-2400 analyzer. Compounds 1, 5 and 12 are obtained according to literature
methods20,22,23
3-(2,2-Dichloroacetyl)-4-hydroxy-1-methylquinolin-2(1H)-one (2)
To a suspension of compound 1 (2.43 gm, 10 mmol) in dioxane (20 mL) sulfuryl chloride (3.3 mL, 40
mmole) was added portionwise, while the temperature was not allowed to rise above 50 °C, where it was
then kept for additional 10 min. The mixture was quickly heated to the boil and poured into ice-water
(100 mL). The solid obtained was filtered and crystallized from toluene to give 2 as yellow crystals, mp
188-190 °C (3.22 g, 51%).21
General procedure for the preparation of compounds 3a-c
The 1,3-binucleophile (10 mmol) was added in one portion to a solution of compound 2 (2.85 g, 10
mmol) in DMF (25 mL) and the mixture was heated under reflux for 4 h. The solid obtained, after cooling
was filtered off and then dried and recrystallized.
1-Methyl-4-hydroxy-3-(2-imino-2H-imidazol-4-yl)quinolin-2(1H)-one (3a)
Obtained from guanidine hydrochloride (0.94 g), crystallized from acetic acid as yellow crystals, mp
273-275 °C (1.93 g, 76%). IR (KBr, cm-1): 3366 (OH), 3206 (NH), 3030 (CHarom.), 2917 (CHaliphatic), 1668
(C=Oquinolinone), 1622 (C=N), 1586 (C=C). 1H-NMR (500 MHz, DMSO-d6), δ: 3.49 (s, 3H, NCH3), 7.21 (t,
1H, J = 7.2 Hz, H-6), 7.59–7.67 (m, 2H, H-8 and H-7), 7.91(s, 1H, CHimidazole), 8.06 (d, 1H, J = 8.0 Hz,
H-5), 9.74 (s, 1H, NH exchangeable with D2O), 12.59 (s, 1H, OH exchangeable with D2O). M/z (relative

HETEROCYCLES, Vol. 85, No. 6, 2012
2429
intensity): 255 [M+ +1, 6], 254 [M+, 33], 228 (20), 221 (11), 200 (18), 188 (25), 175 (100), 172 (21), 147
(24), 146 (20), 134 (23), 115 (14), 106 (14), 104 (24), 77 (34). Anal. Calcd for C13H10N4O2 (254.24): C,
61.41; H, 3.96; N, 22.04%. Found: C, 61.44; H, 3.83; N, 22.01%.
1-Methyl-4-hydroxy-3-(2-cyanoiminoimidazol-4-yl)quinolin-2(1H)-one (3b)
Obtained from cyanoguanidine (0.84 g), crystallized from DMF as yellow crystals, mp 262-264 °C (1.81
g, 65%). IR (KBr, cm-1): 3400 (OH), 3080 (CHarom.), 2924, 2855 (CHaliphatic), 2213 (C≡N), 1629
1
(C=Oquinolinone), 1611 (C=N). H-NMR (500 MHz, DMSO-d6), δ: 3.48 (s, 3H, CH3), 7.32 (t, 1H, J = 7.4
Hz, H-6), 7.64 (d, 1H, J = 8.0 Hz, H-8), 7.89 (t, 1H, J = 7.2 Hz, H-7), 8.01 (d, 1H, J = 8.2 Hz, H-5), 8.15
(s, 1H, CHimidazole), 14.25 (s, 1H, OH exchangeable with D2O). 13C-NMR (125 MHz, DMSO-d6), δ: 30.2,
86.3, 111.1, 117.7, 118.5, 121.9, 123.2, 125.1, 133.9, 135.7, 140.5, 149.1, 152.5, 152.6. M/z (relative
intensity): 279 [M+, 42], 266 (95), 253 (42), 225 (59), 199 (17), 188 (50), 185 (76), 146 (11), 140 (44),
132 (14), 115 (25), 105 (28), 94 (100). Anal. Calcd for C14H9N5O2 (279.26): C, 60.21; H, 3.25; N,
25.08%. Found: C, 60.14; H, 3.22; N, 25.04%.
1-Methyl-4-hydroxy-3-(2-thioxo-1,2-dihydroimidazol-4-yl)quinolin-2(1H)-one (3c)
Obtained from thiourea (0.76 g), crystallized from acetic acid as yellow crystals, mp 255-257 °C (1.81 g,
67%). IR (KBr, cm-1): 3393 (OH), 3074 (CHarom.), 2977, 2833 (CHaliphatic), 1666 (C=Oquinolinone), 1624
(C=N), 1219 (C=S). 1H-NMR (300 MHz, DMSO-d6), δ: 3.63 (s, 3H, NCH3), 7.23 (t, 1H, J = 7.0 Hz, H-6),
7.67 (d, 1H, J = 8.2 Hz, H-8), 7.89 (t, 1H, J = 7.2 Hz, H-7), 8.05 (d, 1H, J = 8.2 Hz, H-5), 8.2 (s, 1H,
CHimidazole), 13.85 (s, 1H, OH exchangeable with D2O). Anal. Calcd for C13H9N3O2S (271.26): C, 57.55;
H, 3.34; N, 15.49; S, 11.80%. Found: C, 57.21; H, 3.12; N, 15.04%.
1-Methyl-4-hydroxy-3-(quinoxalin-2-yl)quinolin-2(1H)-one (4)
A mixture of compound 2 (2.85 g, 10 mmol) and o-phenylenediamine (1.1 g, 10 mmol), in DMF (25 mL),
was heated under reflux for 3 h. The solid obtained during heating was filtered and crystallized from
acetic acid to give 4 as brown crystals, mp 276–279 °C (2.03 g, 67%). IR (KBr, cm-1): 3411 (OH), 3070
(CHarom.), 2979, 2937 (CHaliphatic), 1654 (C=Oquinoline), 1600, 1567 (C=N and C=C). 1H-NMR (500 MHz,
DMSO-d6), δ: 3.63 (s, 3H, NCH3), 7.24 (t, 1H, J = 7.2 Hz, H-6), 7.28 -7.83 (m, 6H, Ar-H), 8.06 (d, 1H, J
= 8.0 Hz, H-5), 8.30 (s, 1H, CHquinoxaline), 13.85 (s, 1H, OH exchangeable with D2O). 13C-NMR (125 MHz,
DMSO-d6), δ: 28.2, 98.7, 111.8, 114.25, 115.8, 119.3, 121.6, 126.0, 128.4, 129.3, 130.0, 132.8, 134.7,
137.8, 144.0, 144.5, 146.2, 153.2. M/z (relative intensity): 304 [M++1, 5], 303 [M+, 81], 293 (13), 288
(14), 285 (37), 281 (36), 280 (20), 253 (38), 252 (30), 250 (100), 249 (17), 220 (34), 218 (36), 214 (31),
202 (20), 185 (25), 136 (38), 134 (50), 128 (29), 118 (25), 97 (48), 77 (65). Anal. Calcd for C18H13N3O2
(303.32): C, 71.28; H, 4.32; N, 13.85%. Found: C, 71.24; H, 4.23; N, 13.74%.
1-Methyl-4-hydroxy3-(8-(4-chlorophenyl)-6-oxo-6H-7,9-dicarbonitrilepyrido[1,2-b][1,2,4]triazin-2-
yl)quinolin-2(1H)-one (6)

2430
HETEROCYCLES, Vol. 85, No. 6, 2012
A mixture of compound 2 (2.85 g, 10 mmol) and 1,6-diamino-4-(4-chlorophenyl)-2-oxo-1,2-
dihydropyridine-3,5-dicarbonitrile (5) (2.85 g, 10 mmol) in DMF (25 mL), was heated under reflux for 3
h. The solid obtained during heating was filtered and crystallized from DMF to give 6 as white crystals,
mp 291-293 °C (3.22 g, 67%). IR (KBr, cm-1): 3357 (OH), 2973, 2930 (CHaliphatic), 2291, 2219 (2C≡N),
1
1686 (C=Opyridone), 1660 (C=Oquinolinone), 1612 (C=N), 1583 (C=C). H-NMR (300 MHz, DMSO-d6), δ:
3.61 (s, 3H, NCH3), 7.34 (t, 1H, J = 6.0 Hz, H-6), 7.44 (d, 2H, Ar-H), 7.56 (d, 1H, J = 6.4 Hz, Ar-H),
7.82 (m, 3H, Ar-H), 8.13 (d, 1H, J = 8.4 Hz, H-5), 8.18 (s, 1H, CHpyridotriazine), 12.81 (bs, 1H, OH
exchangeable with D2O). M/z (relative intensity): 482 [M++2, 7], 481 [M++1, 35], 480 [M+, 100], 479
[M+-1, 10], 453 (27), 452 (27), 424 (15), 396 (3), 382 (2), 265 (37), 266 (12), 240 (5), 225 (2), 200 (22),
146 (10), 132 (14), 120 (8), 105 (5), 104 (6), 77(15). Anal. Calcd for C25H13ClN6O3 (480.87): C, 62.44; H,
2.72; Cl 7.37; N, 17.48%. Found: C, 62.44; H, 2.73; N, 17.44%.
General procedure for the preparation of compounds 7a and 7b
The 1,4-binucleophile (10 mmol) was added in one portion to a solution of compound 2 (2.85 g, 10
mmol) in DMF (25 mL) and the reaction mixture was heated under reflux for 4 h. The solid obtained,
after cooling was filtered off and then dried and recrystallized.
1-Methyl-4-hydroxy-3-(3-imino-2,3-dihydro-1,2,4-triazin-5-yl)quinolin-2(1H)-one (7a)
Obtained from aminoguanidine nitrate (1.37 g), crystallized from DMF as pale yellow crystals, mp
292-294 °C (1.96 g, 73%). IR (KBr, cm-1): 3411 (OH), 3191 (NH), 3070 (CHarom.), 2979, 2937
1
(CHaliphatic), 1654 (C=Oquinoline), 1600, 1567 (C=N). H-NMR (300 MHz, DMSO-d6), δ: 3.61 (s, 3H,
NCH3), 7.30 (t, 1H, J = 6.8 Hz, H-6), 7.51 (d, 1H, J = 8.0 Hz, H-8), 7.86 (t, 1H, J = 7.0 Hz, H-7), 8.07 (d,
1H, J = 8.0 Hz, H-5), 8.16 (s, 1H, Htriazine), 9.02 (s, 1H, =NH exchangeable with D2O), 10.51 (s, 1H, NH
exchangeable with D2O), 13.93 (s, 1H, OH exchangeable with D2O). M/z (relative intensity): 269 [M+, 8],
242 (M+-HCN, 100), 241 (91), 228 (15), 214 (14), 200 (25), 175 (85), 172 (22), 159 (24), 147 (31), 146
(27), 134 (50), 132 (35), 115 (26), 106 (30), 105 (37), 104 (63), 77(16). Anal. Calcd for C13H11N5O2
(269.26): C, 57.99; H, 4.12; N, 26.01%. Found: C, 57.44; H, 4.09; N, 26.04%.
1-Methyl-4-hydroxy-3-(3-thioxo-2,3-dihydro-1,2,4-triazin-5-yl)quinolin-2(1H)-one (7b)
Obtained from thiosemicarbazide (0.91 g), crystallized from DMF as pale brown crystals, mp 282-284 °C
(2.20 g, 77%). IR (KBr, cm-1): 3400 (OH), 3126 (NH), 3030 (CHarom.), 2917 (CHaliphatic), 1668
(C=Oquinolinone), 1623 (C=N). 1H-NMR (500 MHz, DMSO-d6), δ: 3.62 (s, 3H, NCH3), 7.24 (t, 1H, J = 7.2
Hz, H-6), 7.45 (d, 1H, J = 8.0 Hz, H-8), 7.67 (t, 1H, J = 7.2 Hz, H-7), 8.01 (d, 1H, J = 8.0 Hz, H-5), 8.24
(s, 1H, CHtriazine), 12.67 (s, 1H, NH exchangeable with D2O), 14.36 (s, 1H, OH exchangeable with D2O).
13C-NMR (125 MHz, DMSO-d6), δ: 28.6, 102.3, 113.5, 115.3, 122.6, 124.9, 131.3, 136.0, 141.8, 154.1,
159.6, 165.0, 171.5. M/z (relative intensity): 287 [M++1, 19], 286 [M+, 100], 273 (31), 258 (21), 257 (62),
256 (21), 240 (13), 225 (12), 200 (22), 175 (15), 146 (9), 134 (19), 132 (16), 115 (12), 105 (28), 104 (32),

HETEROCYCLES, Vol. 85, No. 6, 2012
2431
77(50). Anal. Calcd for C13H10N4O2S (286.31): C, 54.54; H, 3.52; N, 19.57, S, 11.20%. Found: C, 54.44;
H, 3.53; N, 19.16%.
1-Methyl-4-hydroxy-3-(3-hydrazino-2,3-dihydro-1,2,4-triazin-5-yl)quinolin-2(1H)-one (8)
A mixture of compound 7b (2.86 g, 10 mmol) and hydrazine hydrate (0.58 mL, 12 mmol), in DMF (30
mL), was heated under reflux for 4 h. The solid deposited after cooling was filtered and crystallized from
DMF to give compound 8 as white crystals, mp above 300 °C (1.70 g, 60%). IR (KBr, cm-1): 3411, 3335,
(NH2), 3191, 3100 (OH, NH), 3070 (CHarom.), 2979, 2937 (CHaliphatic), 1654 (C=Oquinoline), 1600, 1567
1
(C=N and C=C). H-NMR (300 MHz, DMSO-d6), δ: 3.44 (s, 3H, NCH3), 7.26 (t, 1H, J = 7.2 Hz, H-6),
7.53 (d, 1H, J = 8.0 Hz, H-8), 7.71 (t, 1H, J = 7.2 Hz, H-7), 7.93 (d, 1H, J = 8.0 Hz, H-5), 8.25 (s, 1H,
CHtriazine), 8.43 (s, 2H, NH2 exchangeable with D2O), 9.99 (s, 1H, NH exchangeable with D2O), 13.36 (s,
1H, OH exchangeable with D2O). M/z (relative intensity): 285 [M++1, 17], 284 [M+, 100], 256 (25), 255
(6), 254 (11), 216 (96), 215 (19), 214 (69), 172 (51), 146 (66), 132 (57), 115 (29), 105 (14), 104 (22),
77(67). Anal. Calcd for C13H12N6O2 (284.28): C, 54.93; H, 4.25; N, 29.56%. Found: C, 54.84; H, 4.23; N,
29.54%.
1-Methyl-4-hydroxy-3-[1,2,4-triazolo[4,3-b][1,2,4]triazin-7-yl]quinolin-2(1H)-one (9)
A solution of compound 8 (2.84 g, 10 mmol) in triethyl orthoformate (8.16 mL, 48 mmol) was heated
under fusion for 2 h. The precipitate so formed on hot was filtered and crystallized from acetic acid to
give compound 9 as pale yellow crystals, mp above 300 °C (1.85 g, 63%). IR (KBr, cm-1): 3446 (OH),
1
3075 (CHarom.), 2977, 2934 (CHaliphatic), 1673 (C=Oquinolinone), 1634 (C=N), 1598 (C=C). H-NMR (300
MHz, DMSO-d6), δ: 3.47 (s, 3H, NCH3), 7.24 (t, 1H, J = 6.0 Hz, H-6), 7.47 (d, 1H, J = 8.0 Hz, H-8), 7.67
(t, 1H, J = 6.4 Hz, H-7), 7.99 (d, 1H, J = 8.4 Hz, H-5), 8.01, 8.24 (2s, 2H, Htriazine and Htriazole), 14.36 (bs,
1H, OH exchangeable with D2O). 13C-NMR (75 MHz, DMSO-d6), δ: 28.2, 99.3, 113.3, 117.0, 118.9,
124.7, 125.4, 139.0, 141.5, 154.1, 156.4, 159.4, 163.0, 166.4. Anal. Calcd for C14H10N6O2 (294.27): C,
57.14; H, 3.43; N, 28.56%. Found: C, 57.12; H, 3.33; N, 28.54%.
5-Amino-1-[5-(4-hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-yl)-[1,2,4]triazine-3-yl]-3-methyl-
sulfanyl-1H-pyrazole-4-carbonitrile (10)
A mixture of compound 8 (2.84 g, 10 mmol) and [bis(methylthio)methylene]malononitrile (1.70 gm, 10
mmol), in DMF (25 mL) was heated under reflux for 4 h. The reaction solution was left to cool at room
temperature and the solid so formed was filtered and crystallized from dioxane to give compound 10 as
pale yellow crystals, mp above 300 °C (2.48 g, 61%). IR (KBr, cm-1): 3400 (OH), 3323, 3183 (NH2),
3080 (CHarom.), 2924, 2855 (CHaliphatic), 2214 (C≡N), 1671(C=Oquinolinone), 1629 (C=N), 1611 (C=C).
1H-NMR (300 MHz, DMSO-d6), δ: 2.88 (s, 3H, SCH3), 3.61 (s, 3H, NCH3), 5.22 (bs, 2H, NH2
exchangeable with D2O), 7.22 (t, 1H, J = 6.2 Hz, H-6), 7.49 (d, 1H, J = 8.2 Hz, H-8), 7.77 (t, 1H, J = 6.4

2432
HETEROCYCLES, Vol. 85, No. 6, 2012
Hz, H-7), 8.13 (d, 1H, J = 8.0 Hz, H-5), 8.23 (s, 1H, CHtriazine), 12.28 (bs, 1H, OH exchangeable with
D2O). Anal. Calcd for C18H14N8O2S (406.43): C, 53.20; H, 3.47; N, 27.57; S, 7.89%. Found: C, 53.12; H,
3.43; N, 27.44; S, 7.85%.
1-Methyl-4-hydroxy-3-[2-(6-methyl-5-oxo-3-thioxo-2,3dihydro-1,2,4-triazin-4(5H)-ylimino)acetyl]-
quinolin-2(1H)-one (12)
A mixture of compound 2 (2.85 g, 10 mmol) and aminotriazine 11 (1.58 g, 10 mmol), in pyridine (30 mL),
was heated under reflux for 4 h. Then, the solution was filtered and the clear solution was acidified by
dilute HCl. The precipitate so formed was filtered, washed several times with water, air dried and
crystallized from ethanol to give 12 as yellow crystals, mp 236-237 °C (2.22 g, 60%). IR (KBr, cm-1):
3419 (OH), 2981, 2934 (CHaliphatic), 1709 (C=O), 1667, 1632 (C=Otriazinone and C=Oquinolinone), 1599, 1575
(C=N and C=C). 1H-NMR (300 MHz, DMSO-d6), δ: 3.23 (s, 3H, CH3 triazine), 3.68 (s, 3H, NCH3), 5.93 (s,
1H, CH=N), 7.20 (t, 1H, J = 6.2 Hz, H-6), 7.44 (d, 1H, J = 8.0 Hz, H-8), 7.61 (t, 1H, J = 6.4 Hz, H-7),
7.89 (d, 1H, J = 8.4 Hz, H-5), 11.39 (bs, 1H, NH exchangeable with D2O), 13.23 (bs, 1H, OH
exchangeable with D2O). 13C-NMR (75 MHz, DMSO-d6), δ: 13.6, 28.6, 61.8, 102.6, 113.8, 115.5, 117.0,
122.8, 125.2, 136.2, 142.0, 153.3, 160.1, 163.0, 171.8, 190.4. M/z (relative intensity): 371 [M+, 16], 343
(17), 326 (23), 292 (16), 278 (16), 275 (27), 269 (60), 241 (14), 223 (32), 197 (30), 175 (20), 174 (22),
158 (7), 146 (43), 136 (16), 132 (79), 114 (13), 105 (27), 104 (33), 77(79), 63 (100). Anal. Calcd for
C16H13N5O4S (371.38): C, 51.75; H, 3.53; N, 18.86, S, 8.63%. Found: C, 51.74; H, 3.53; N, 18.74; S,
8.53%.
General procedure for the preparation of compounds 13, 14 and 15
Hydrazine hydrate (12 mmol), guanidine hydrochloride (10 mmol) and/or o-phenylenediamine (10 mmol)
was added to a solution of compound 12 (3.71 g, 10 mmol) in DMF (25 mL) and the reaction mixture was
refluxed for 4 h. The solid obtained after cooling was filtered off and then dried and recrystallized to give
compounds 13, 14 and 15 respectively.
5-Methyl-3-[(6-methyl-5-oxo-3-thioxo-2,5-dihydro-3H-1,2,4-triazin-4-ylimino)methyl]-1,5-dihydro-
pyrazolo[4,3-c]quinolin-4-one (13)
Obtained from hydrazine hydrate (0.58 mL, 12 mmol), crystallized from DMF as yellow crystals, mp
above 300 °C (2.27 g, 62%). IR (KBr, cm-1): 3292 (NH), 2978, 2870 (CHaliphatic), 1662, 1630 (C=Otriazinone
1
and C=Oquinolinone), 1603, 1572 (C=N and C=C). H-NMR (300 MHz, DMSO-d6), δ: 2.88 (s, 3H, CH3
triazine), 3.63 (s, 3H, NCH3), 5.57 (s, 1H, CH=N), 7.28 (t, 1H, J = 6.2 Hz, H-8), 7.32 (d, 1H, J = 8.0 Hz,
H-6), 7.77 (t, 1H, J = 6.4 Hz, H-7), 8.13 (d, 1H, J = 8.4 Hz, H-9), 10.53 (bs, 1H, NH exchangeable with
13
D2O), 13.83 (bs, 1H, NH exchangeable with D2O). C-NMR (75 MHz, DMSO-d6), δ: 16.2, 28.9, 62.9,
98.2, 114.5, 118.2, 119.9, 120.7, 122.2, 124.2, 128.5, 135.5, 145.4, 153.7, 155.6, 176.7. M/z (relative
intensity): 367 [M+, 25], 366 [M+ -1, 20], 326 (27), 303 (25), 278 (26), 258 (20), 255(26), 249 (21), 201

HETEROCYCLES, Vol. 85, No. 6, 2012
2433
(21), 175 (21), 148 (31), 134 (22), 115 (26), 105 (22), 104 (27), 86(100), 77 (36). Anal. Calcd for
C16H13N7O2S (367.39): C, 52.31; H, 3.57; N, 26.69, S, 8.73%. Found: C, 52.21; H, 3.53; N, 26.64; S,
8.63%.
2-Imino-6-methyl-4-[(6-methyl-5-oxo-3-thioxo-2,5-dihydro-3H-1,2,4-triazin-4-ylimino)methyl]-2,6-
dihydro-1H-pyrimido[5,4-c]quinolin-5-one (14)
Obtained from guanidine hydrochloride (0.94 g, 10 mmol), crystallized from acetic acid as pale yellow
crystals, mp above 300 °C (2.40 g, 61%). IR (KBr, cm-1): 3253 (NH), 3072 (CHarom.), 2977, 2932
(CHaliphatic), 1674, 1634 (C=Otriazinone and C=Oquinolinone), 1599, 1569 (C=N and C=C). 1H-NMR (300 MHz,
DMSO-d6), δ: 2.88 (s, 3H, CH3 triazine), 3.61 (s, 3H, NCH3), 5.86 (s, 1H, CH=N), 7.22 (t, 1H, J = 6.4 Hz,
H-9), 7.43 (d, 1H, J = 8.4 Hz, H-7), 7.67 (t, 1H, J = 6.2 Hz, H-8), 8.10 (d, 1H, J = 8.0 Hz, H-10), 8.78 (bs,
1H, NH exchangeable with D2O), 11.37 (bs, 1H, NH exchangeable with D2O), 12.23 (bs, 1H, NH
exchangeable with D2O). M/z (relative intensity): 394 [M+, 11], 393 [M+-1, 13], 379 (11), 365 (12), 331
(14), 322 (100), 321 (60), 294 (65), 268 (46), 266 (22), 257 (11), 240 (13), 189 (11), 175 (10), 146 (23),
132 (33), 132 (16), 115 (14), 108 (25), 105 (12), 93 (22), 77 (42). Anal. Calcd for C17H14N8O2S (394.41):
C, 51.77; H, 3.58; N, 28.41; S, 8.13%. Found: C, 51.74; H, 3.53; N, 28.14; S, 8.09%.
8-Methyl-6-[(6-methyl-5-oxo-3-thioxo-2,5-dihydro-3H-1,2,4-triazin-4-ylimino)methyl]-13H-benzo-
[1,5]diazepino[6,5-c]quinolin-7(8H)-one (15)
Obtained from o-phenylenediamine (1.1 g, 10 mmol), crystallized from acetic acid as pale yellow crystals,
mp above 300 °C (2.91 g, 66%). IR (KBr, cm-1): 3294, 3252 (NH), 2980, 2934 (CHaliphatic), 1670, 1632
(C=Otriazinone and C=Oquinolinone), 1603, 1583 (C=N and C=C). 1H-NMR (300 MHz, DMSO-d6), δ: 3.15 (s,
3H, CH3 triazine), 3.63 (s, 3H, NCH3), 5.87 (s, 1H, CH=N), 7.23 (t, 1H, J = 6.4 Hz, Ar-H), 7.36 (d, 1H, J =
8.2 Hz, Ar-H), 7.42 (t, 1H, J = 6.4 Hz, Ar-H), 7.86-8.13 (m, 5H, Ar-H), 9.95 (s, 1H, NH exchangeable
13
with D2O). 12.79 (bs, 1H, NH exchangeable with D2O). C-NMR (75 MHz, DMSO-d6), δ: 16.2, 29.1,
62.1, 92.2, 113.6, 114.3, 115.7, 117.0, 119.6, 127.2, 128.1, 129.2, 129.7, 130.4, 134.5, 138.5, 146.2, 152.2,
152.6, 157.3, 165.2, 174.9. Anal. Calcd for C22H17N7O2S (443.49): C, 59.58; H, 3.86; N, 22.11, S, 7.23%.
Found: C, 59.54; H, 3.83; N, 22.02.
Antimicrobial Activity
The standardized disc agar diffusion method29 was followed to determine the activity of the synthesized
compounds against the sensitive organisms Staphylococcus aureus as a Gram positive bacterium, Proteus
vulgaris and Klebsiella as Gram negative bacteria and Candida albicans as a fungus strain. The antibiotic
Doxymycin and Fluconazole were used in concentration 100 µg mL-1, as references for antibacterial and
antifungal agents. The compounds were dissolved in DMSO which has no inhibition activity to get
concentration of 100 µg mL-1. The test was performed on medium potato dextrose agars (PDA) which

2434
HETEROCYCLES, Vol. 85, No. 6, 2012
contain infusion of 200 g potatoes, 6 g dextrose and 15 g agar.30 Uniform size filter paper disks (3 disks
per compound) were impregnated by equal volume (10 µL) from the specific concentration of dissolved
tested compounds and carefully placed on inoculated agar surface. After incubation for 36 h at 27 °C in
the case of bacteria and for 48 h at 24 °C in the case of fungi, inhibition of the organisms was measured
and used to calculate mean of inhibition zones.
Antitumor activity
EAC cells were maintained by weekly intraperitoneal transplantation of 2.5 Х 105 cells in mice. The
tumor is characterized by a moderately rapid growth, which leads to the death of the mice in about 20
days due to the distal metastasis. Ascites was withdrawn under aseptic conditions from the peritoneal
cavity of tumor bearing mice by needle aspiration after 7 days of EAC cells inoculation. To adjust the
number of EAC cells/mL, tumor cells obtained were diluted several times with normal saline. EAC viable
cells were counted by trypan blue exclusion method where 10 µl trypan blue (0.05%) was mixed with 10
µl of the cell suspension. Within 5 min, the mixture was spread onto haemocytometer, covered with a
cover slip and then the cells were examined under microscope. Dead cells are blue stained viable cells are
not.31 Cell suspension was adjusted to contain 2.5 X 105 viable cells/ml. EAC cells, RPMI medium drugs,
and DMSO were added in sterile test tubes according to trypan blue exclusion method.31 The cells were
incubated for two hours at 37 °C under a constant over lay of 5% CO2. EAC viable cells were counted by
trypan blue exclusion using haemocytometer as mentioned above. The cell surviving fraction was
calculated from the relation T/C; where T and C represent the number of viable cells in a unit volume and
the number of total (viable + dead) cells in the same unit volume, respectively.
REFERENCES
1. R. Tedesco, D. Chai, M. G. Darcy, D. Dhanak, D. M. Fitch, A. Gates, V. K. Johnston, R. M. Keenan,
J. Lin-Goerke, R. T. Sarisky, A. N. Shaw, K. L. Valko, K. J. Wiggall, M. N. Zimmerman, and K. J.
Duffy, Bioorg. Med. Chem. Lett., 2009, 19, 4354.
2. D. K. Hutchinson, C. A. Flentge, P. L. Donner, R. Wagner, C. J. Maring, W. M. Kati, Y. Liu, S. V.
Masse, T. Middleton, H. Mo, D. Montgomery, W. W. Jiang, G. Koev, D. W. A. Beno, K. D. Stewart,
V. S. Stoll, A. Molla, and D. J. Kempf, Bioorg. Med. Chem. Lett., 2011, 21, 1876.
3. T. Shiro, H. Takahashi, K. Kakiguchi, Y. Inoue, K. Masuda, H. Nagata, and M. Tobe, Bioorg. Med.
Chem. Lett., 2012, 22, 285.
4. S. G. Durón, A. Lindstrom, C. Bonnefous, Z. Hui, C. Xiaohong, K. T. Symons, M. Sablad, N.
Rozenkrants, Y. Zhang, Li. Wang, Y. Nahid, A. K. Shiau, S. A. Noble, P. Rix, T. S. Rao, C. A.
Hassig, and N. D. Smith, Bioorg. Med. Chem. Lett., 2012, 22, 1237.
5. L. C. Tavares, S. Johann, T. M. A. Alves, J. C. Guerra, E. M. de Souza-Fagundes, C. P. Silva, A. J.

HETEROCYCLES, Vol. 85, No. 6, 2012
2435
Bortoluzzi, G. F. Caramori, R. M. Braibante, H. T. S. Braibante, M. E. F. Braibante, and M. G.
Pizzolatti, Eur. J. Med. Chem., 2011, 46, 4448.
6. R. G. Kalkhambkar, G. Aridoss, G. M. Kulkarni, R. M. Bapset, T. Y. Mudaraddi, N. Premkumar,
and Y. T. Jeong, Monatsh. Chem., 2011, 142, 305.
7. R.-H. Guo, Q. Zhang, Y.-B. Maa, X.-Y. Huang, J. Luo, L.-J. Wang, C.-A. Geng, X.-M. Zhang, J. Z.
Zhou, Z.-Y. Jiang, and J.-J. Chen, Bioorg. Med. Chem., 2011, 19, 1400.
8. R.-H. Guo, Q. Zhang, Y.-B. Maa, J. Luo, C.-A. Geng, L.-J. Wang, X.-M. Zhang, J. Z. Zhou, Z.-Y.
Jiang, and J.-J. Chen, Eur. J. Med. Chem., 2011, 46, 307.
9. F. Curreli, H. Zhang, X. Zhang, I. Pyatkin, Z. Victor, A. Altieri, and A. K. Debnath, Bioorg. Med.
Chem., 2011, 19, 77.
10. M. J. López Rivilli, E. L. Moyano, and G. I. Yranzo, Tetrahedron Lett., 2010, 51, 478.
11. M. S. Christodoulou, S. Liekens, K. M. Kasiotis, and S. A. Haroutounian, Bioorg. Med. Chem., 2010,
18, 4338.
12. J. Pawlas, P. Vedso, P. Jakobsen, P. O. Huusfeldt, and M. Begtrup, J. Org. Chem., 2000, 65, 9001.
13. M. Sankaran, C. Kumarasamy, U. Chokkalingam, and P. S. Mohan, Bioorg. Med. Chem. Lett., 2010,
20, 7147.
14. F. Pierre, S. E. O’Brien, M. Haddach, P. Haddach, M. K. Schwaebe, E. Stefan, L. Darjania, R.
Darjania, C. Ho, A. Siddiqui-Jain, N. Streiner, W. G. Rice, K. Anderes, and D. M. Ryckman, Bioorg.
Med. Chem. Lett., 2011, 21, 1687.
15. E. Rajanarendar, M. N. Reddy, K. R. Murthy, K. G. Reddy, S. Raju, M. Srinivas, B. Praveen, and M.
S. Rao, Bioorg. Med. Chem. Lett., 2010, 20, 6052.
16. J. C. Bressi, R. Jong, Y. Wu, A. J. Jennings, J. W. Brown, S. O’Connell, L. W. Tari, R. J. Skene, P.
Vu, M. Navre, X. Cao, and A. R. Gangloff, Bioorg. Med. Chem. Lett., 2010, 20, 3138.
17. K. Sztanke, K. Pasternak, J. Rzymowska, M. Sztanke, and M. Kandefer-Szerszen, Eur. J. Med.
Chem., 2008, 43, 1085.
18. K. Sztanke, K. Pasternak, B. Rajtar, M. Sztanke, M. Majekc, and M. Polz-Dacewicz, Bioorg. Med.
Chem., 2007, 15, 5480.
19. T. Gucký, I. Fryšová, J. Slouka, M. Hajdúch, and K. P. Džubá, Eur. J. Med. Chem., 2009, 44, 891.
20. P. Roschger, W. Fiala, and W. Stadlbauer, J. Heterocycl. Chem., 1992, 29, 225.
21. K. Faber and T. Kappe, J. Heterocycl. Chem., 1984, 21, 1881.
22. A. A. A. Al-Najjar, S. A. Amer, M. Riad, I. Elghamy, and M. H. Elnagdi, J. Chem. Res., 1996, 296.
23. A. Dornow and M. P. Menzel, Chem. Ber., 1964, 97, 2173.
24. Z. El-Gendy, J. M. Morsy, H. A. Allimony, W. R. Abdel-Monem, and R. M. Abdel-Rahman,
Phosphorus, Sulfur, Silicon, Relat. Elem., 2003, 178, 2055.

2436
HETEROCYCLES, Vol. 85, No. 6, 2012
25. P. D'Arpa and L. F. Liu, Biochim. Biophys. Acta, 1989, 989, 163.
26. N. K. Sharma, Y. Kumar, and S. Sahi, Int. J. Pharmacy Pharm. Sci., 2010, 2 suppl 2, 118.
27. S. A. EL-Naggar, A. A. El-Barbary, M. A. Mansour, F. Abdel-Shafy, and S. Talat, Int. J. Cancer
Res., 2011, 7, 278.
28. Y. Xia, Z. Y. Yang, S. L. Morris-Natschke, and K. H. Lee, Eur. J. Med. Chem., 2010 45, 4188.
29. A. U. Rahman, M. I. Choudhary, and W. J. Thomsen, Bioassay Techniques for Drug Development,
Harwood Academic Publishers: The Netherlands, 2001.
30. K. M. Khan, Z. S. Saify, A. K. Zeesha, M. Ahmed, M. Saeed, M. Schick, H. J. Kohlbau, and W.
Voelter, Arzneim. Forsch., 2000, 50, 915.
31. D. A. Riberio, M. E. Marques, and D. M. Salvadori, Braz. Dent. J., 2006, 17, 228.